1. Novozymes and Christian Hansen merged to form Novonesis, a company with strong business and stable margins but declining growth rates. 2. Despite Q3/24 results, long-term growth has slowed, and management expects future revenue acceleration and margin improvements. 3. Intrinsic value calculations suggest cautious investment due to the stock not being a bargain unless very optimistic growth assumptions are met.